Albertsons' Opioid Settlement Widens Loss

Albertsons reported a widened GAAP loss in its fourth quarter, primarily due to a significant opioid settlement. This financial impact overshadowed positive developments, including an increased dividend and a share repurchase hike. The settlement highlights the substantial financial liabilities that can arise from legal challenges, even for established retail companies. Investors will be closely monitoring how the company manages these costs and their long-term effect on profitability and shareholder returns.